Journal profile · IMMUNOLOGY
Frontiers in Immunology
ISSN 1664-3224 · Frontiers Media S.A. · SWITZERLAND
Frontiers in Immunology: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 6.95; fully open access; APC charged, amount not published; median 63 days to acceptance (292 articles, last 24 months); 7,028 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Frontiers in Immunology is published by Frontiers Media S.A. and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Immune Cell Function and Interaction, T-cell and B-cell Immunology and Cancer Immunotherapy and Biomarkers, together about 30.3% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)
Frontiers in Immunology is a multidisciplinary journal that publishes research across basic, translational, and clinical immunology. The journal aims to showcase advances and novel approaches to diagnosing and treating immune disorders in both animal and cellular models, as well as in humans. Indexed in MEDLINE, PubMed Central, Scopus and the SCIE Frontiers in Immunology is the official Journal of the International Union of Immunological Societies (IUIS). Led by Field Chief Editor Pietro Ghezzi (Emeritus Professor at Brighton and Sussex Medical School), Frontiers in Immunology welcomes contributions that investigate the basic mechanisms of immune system development and function, with a particular emphasis on describing the clinical and immunological phenotype of human immune disorders and defining their molecular basis. Topics include: advances in biological drugs immune system development and function molecular basis of human immune disorders novel approaches to diagnosis and treatment of immune disorders precision medicine for immunological disorders studies on animal and cellular models and in humans studies on systems immunology with relevant experimental validation. Frontiers in Immunology particularly welcomes news ideas and approaches which supports and advances the UN’s Sustainable Development Goal (SDGs), specifically SDG 3: good health and well-being. The research published in this journal could lead to the development of new treatments and therapies for various immunological disorders, thereby promoting well-being for all. Manuscripts that focus on clinical studies, medical treatments, or human diseases without a clear connection to immunology are not suitable for publication in this journal. Additionally, studies that use analytical molecular biology techniques without a clear immunological context or contribution to the field of immunology are also not within the scope of this journal. Manuscripts focusing solely on cost-effectiveness studies are also not considered for publication in this journal. Frontiers’ journals require that manuscripts primarily comprising computational studies of public data, must include appropriate validation. Please refer to the Frontiers Standards for research methodology policy, for more information. Manuscripts not adhering to these standards will not be considered. Frontiers in Immunology is dedicated to propelling advancements in the field of Immunology by providing unrestricted access to articles and dissemina
From the journal's Aims & Scope
Research area (LetPub): IMMUNOLOGY
Editorial board by country: none in mainland China; most named United States 5, Italy 4, Australia 2, Singapore 2, United Kingdom 1 (18 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Immune Cell Function and InteractionImmunology and Microbiology13.3%
- T-cell and B-cell ImmunologyImmunology and Microbiology9%
- Cancer Immunotherapy and BiomarkersMedicine8%
- Immunotherapy and Immune ResponsesImmunology and Microbiology7.7%
- Immune cells in cancerImmunology and Microbiology6.8%
- Immune Response and InflammationImmunology and Microbiology4.8%
- CAR-T cell therapy researchMedicine4.6%
- Ferroptosis and cancer prognosisMedicine3.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Immunology | Zone 2 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Immunology | Zone 2 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Immunology | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of ScienceMEDLINEPMCEmbasePublisher website
Other: EBSCO, ProQuest, Dimensions, CNKI, CLOCKSS, Crossref
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 6.95LetPub ·
- Impact factor (publisher)
- 7Publisher website ·
- CiteScore 2026-06
- 11.3LetPub ·
- CiteScore (publisher)
- 11.3Publisher website ·
- SJR 2026-06
- 1.96LetPub ·
- SNIP 2026-06
- 1.43LetPub ·
- h-index
- 84LetPub ·
- h-index
- 360OpenAlex ·
- i10-index
- 31,801OpenAlex ·
- 2-year mean citedness
- 5.53OpenAlex ·
- Self-citation rate
- 7.1%LetPub ·
- Share of gold OA articles
- 99.9%LetPub ·
Volume
- Articles per year
- 6,551LetPub ·
Articles by year OpenAlex count · 57,680 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 7,825 | 7,825 | 4,765 |
| 2025 | 7,028 | 7,028 | 38,374 |
| 2024 | 5,525 | 5,525 | 69,530 |
| 2023 | 6,502 | 6,502 | 134,166 |
| 2022 | 8,221 | 8,221 | 228,131 |
| 2021 | 6,129 | 6,129 | 243,600 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
63 daysMedian, submission to acceptance · P25–P75 44 days – 90 days
- Acceptance to online
- median 17 days (292 articles)
- Submission to online
- median 82 days
- Sample
- 292 articles with submission and acceptance dates (15,862 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 14 weeksLetPub ·
- Submission to publication (journal-reported)
- about 14 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | CHF 3,150 | Yes | CC BY | |
| OpenAlex | CHF 3,150 | — | — | |
| LetPub | USD 3,295 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteAI use, Conflicts of interest, License & copyright, Open access, Peer review
- AI use Use of AI to create written or visual content
Authors should not list a generative AI technology as a co-author or author of any submitted manuscript. Generative AI technologies cannot be held accountable for all aspects of a manuscript and consequently do not meet the criteria required for authorship. If the author of a submitted manuscript has used written or visual content produced by or edited using a generative AI technology, this use mu…
Source ↗Publisher website ·- Conflicts of interest Safeguards against financial conflicts of interest
Only leading researchers acting as Associate Editors, who are not part of Frontiers' staff, can make acceptance decisions based on reviews performed by external experts acting as Community Reviewers or Reviewers. None have a financial incentive to accept articles, i.e. they are not paid for their role as Associate Editor or community Reviewer, and any award scheme is not linked to acceptances of m…
Source ↗Publisher website ·- License & copyright Open access and copyright
Figures, tables, and images are published under a Creative Commons CC-BY license; permission must be obtained for copyrighted material from other sources. Model summary
All Frontiers' articles from July 2012 onwards are published with open access under the Creative Commons CC-BY license (the current version is CC-BY, version 4.0). This means that the author(s) retains copyright, but the content is free to download, distribute, and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article. Upon submission, the author(s)…
Source ↗Publisher website ·- Open access Open access and copyright
Articles from July 2012 onwards are open access under CC-BY version 4.0; authors retain copyright. Model summary
All Frontiers' articles from July 2012 onwards are published with open access under the Creative Commons CC-BY license (the current version is CC-BY, version 4.0). This means that the author(s) retains copyright, but the content is free to download, distribute, and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article. Upon submission, the author(s)…
Source ↗Publisher website ·- Peer review Peer review
CrossMark policy: readers can locate the current version of content; Frontiers maintains published content and alerts readers to changes. Model summary
Our rigorous, transparent peer review process combines expert review and constructive dialogue to strengthen your manuscript.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Frontiers Media S.A.
- Country or region
- SWITZERLAND
- Language
- English
- ISSN
- 1664-3224
- Society / sponsor
- International Union of Immunological Societies
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Frontiers in Immunology
What CAS zone is Frontiers in Immunology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Frontiers in Immunology is in Zone 2 of Medicine, and in Zone 2 of the minor category Immunology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Frontiers in Immunology?
The latest impact factor listed by LetPub is 6.95; CiteScore 11.3, h-index 360.
How long does peer review take at Frontiers in Immunology?
Based on the dates recorded on 292 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 63 days (interquartile range 44–90 days); authors report an average review time of about 14 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Frontiers in Immunology based?
Of the 18 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (5), Italy (4) and Australia (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Frontiers in Immunology?
According to LetPub and DOAJ records, Frontiers in Immunology is indexed in SCIE, Scopus and DOAJ. The journal's website also lists Web of Science, MEDLINE, PMC and Embase; that list has not been checked against each database.
Is Frontiers in Immunology open access, and what is the APC?
Frontiers in Immunology is a fully open-access journal. APC charged, amount not published.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .